Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug



    HILTON HEAD ISLAND, S.C., Sept. 9 /CNW/ -- At approximately 3:21 PM
today, Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us,
agreed to act as a conduit to provide samples of Global Humanceuticals,
Inc's., new extremely effective, safe and stable drug candidate to profit,
non-profit, academic, government, non-government, U.S. and foreign
institutions, organizations, and corporations, under mutual agreements,
contracts or partnerships, to spur theoretical, objective, mechanistic,
developmental or clinical research. This unique new chemical entity is
referred to as compound NIAID No.11039. However, this invention has already
received a patent called: Antiviral Composition, U.S. patent number: 6,821,958
on November 23, 2004. The World International Patent Organization published
the International Application Number as PCT/US2005/039528 on November 5, 2006.
    "This gift is intended to extend technology that no one else posses on
this planet." Stated Dr. Hershline. "Already, Chinese scientists are very
interested."  Dr. Hershline hosted Session V at the World Aids Day Conference
China Dec 1 to Dec 3, 2006, to initially present data an NIAID No.11039. 
There was, unfortunately, a communication error from the National Institute of
Health (NIH of the United States) to Dr. Hershline, which prevented
presentation of test results.
    The compound has a non-toxic alpha-glucose backbone, obtained from an
abundant natural source.  The backbone is chemically bi-substituted in a
random fashion, by a new reaction.  "The substitution groups are different
sulfur based viral de-activating groups that work together to provide viral
entry inhibition at concentrations of one pico-Molar.  This active
concentration is equivalent to diluting a 1% solution one million times.
    The random substitutions are intended to prevent the virus from escaping
de-activation thru mutation.  "Global Humanceuticals, Inc.'s NIAID No.11039 is
the first drug designed to prevent the development of resistance, the biggest
nightmare in HIV treatment," stated Dr. Hershline.
    "I think we have to talk in terms of a cure for HIV.  I want to cure HIV
and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.
    Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru
CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467,
Hilton Head Is., SC, 29925, by fax: 843-342-5924, phone:  843-342-5900. Direct
to Dr. Hershline:  843-683-3683.




For further information:

For further information: Dr. Roger Kenneth Hershline PhD MD, CEO of
Global  Humanceuticals, Inc., +1-843-342-5900, direct, +1-843-683-3683, fax, 
+1-843-342-5924, Roger@CureHIV.us Web Site: http://www.curehiv.us

Organization Profile

GLOBAL HUMANCEUTICALS, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890